Clinical3 days agoNew
Personalized cancer vaccine reduces risk of recurrence in high-risk melanoma - springermedicine.com
Personalized cancer vaccine reduces risk of recurrence in high-risk melanoma springermedicine.com
Biogenea advances its quantum-classical AI vaccine platform across three distinct indications, including MSS colorectal cancer where it combines with standard chemo-immunotherapy.trial
Meanwhile, ZSky Biotech initiates a Phase II trial for glioblastoma using personalized dendritic cell vaccines, and new structural biology insights clarify how neoantigen-specific TCRs discriminate self from non-self.trialNature
Personalized cancer vaccine reduces risk of recurrence in high-risk melanoma springermedicine.com
Personalized Cancer Vaccines Slash Recurrence Risk by 49% in Trials 조선일보
Relevant work from earlier we're still surfacing — not today's news.